MNMD vs. ARWR, CGON, GMTX, TVTX, RXRX, TARS, BEAM, APGE, SDGR, and CNTA
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Arrowhead Pharmaceuticals (ARWR), CG Oncology (CGON), Gemini Therapeutics (GMTX), Travere Therapeutics (TVTX), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Schrödinger (SDGR), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.
Mind Medicine (MindMed) vs.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
In the previous week, Arrowhead Pharmaceuticals had 25 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 34 mentions for Arrowhead Pharmaceuticals and 9 mentions for Mind Medicine (MindMed). Mind Medicine (MindMed)'s average media sentiment score of 1.23 beat Arrowhead Pharmaceuticals' score of 0.83 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media.
Arrowhead Pharmaceuticals presently has a consensus price target of $42.13, suggesting a potential upside of 175.15%. Mind Medicine (MindMed) has a consensus price target of $25.11, suggesting a potential upside of 261.83%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Arrowhead Pharmaceuticals.
Mind Medicine (MindMed) has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Mind Medicine (MindMed) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Mind Medicine (MindMed)'s return on equity of -47.56% beat Arrowhead Pharmaceuticals' return on equity.
Arrowhead Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.
Arrowhead Pharmaceuticals received 494 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 93.44% of users gave Mind Medicine (MindMed) an outperform vote while only 65.44% of users gave Arrowhead Pharmaceuticals an outperform vote.
Summary
Mind Medicine (MindMed) beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
This page (NASDAQ:MNMD) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy MNMD Stock Free MNMD Stock Alerts